Gary Gillheeney on product pipeline
From ITCO Episode 12: Gary Gillheeney, Sr., President & CEO of Organogenesis · · New England Council
“Our most exciting pipeline product, 'RENEW', is designed to address significant unmet medical needs in osteoarthritis, a $4 billion chronic inflammatory and degenerative condition market affecting more than 30 million Americans.”
On , Gary Gillheeney, President, Chief Executive Officer, Chair of the Board at ORGANOGENESIS HOLDINGS INC, spoke about product pipeline during ITCO Episode 12: Gary Gillheeney, Sr., President & CEO of Organogenesis on New England Council.
About Gary Gillheeney
In a September 2024 interview, Gary Gillheeney stated that Organogenesis has grown annual revenues by nearly 400% to about $400 million and more than doubled its employee base to approximately 900, achieving profitability in 2020. He described the company's mission as providing solutions that improve lives while lowering the overall cost of care, and said its portfolio addresses every type of chronic wound in all sites of care except third-degree burns. Gillheeney noted that chronic wounds affect over 7 million Americans annually and that, if left untreated, as many as 30% of these wounds can result in amputation, citing a five-year post-amputation mortality rate of 50%. Gillheeney said the company has lobbied CMS and congressional delegations about proposed Medicare payment methodologies for skin substitutes, expressing concern that the changes could affect patient access and potentially lead to avoidable amputations and exacerbate health inequities. He highlighted that disparities in social determinants of health have a profound impact on wound healing, with amputations being substantially more prevalent in racial and ethnic minority populations. Gillheeney also discussed the company's pipeline product "RENEW," which he described as designed to address unmet medical needs in osteoarthritis, a market affecting more than 30 million Americans.